*Indicates Young Investigator
Travel and arrival day
Social event: Creole Queen Dinner Jazz Cruise: Listen to a live jazz band as you dine on a Creole buffet.
Purchase your ticket here: https://www.bigeasy.com/negotiated-tours/microphysiological-systems-world-summit
1. Lessons Learned Engineering MPS platforms as a Physiologist
Jenn Fang, Tulane University, USA and Will Bralower, Aracari Biosciences, USA
2. The Translational Organ-on-Chip Platform (TOP), an open platform for modular interfacing of organs-on-chips
Andries Van der Meer, Anke Vollertsen, Eric R. Safai, University of Twente, Netherlands
3. Considerations in setting up a high-throughput organ-on-a-chip culture
Kristin Bircsak, Divya Iyer, MIMETAS, Netherlands
4. New MPS based in vitro models for immuno-oncological applications: circulating immune cells and 3D tissue models cross-talk
Maurizio Aiello, React4Life, Italy
5. Applications of mathematical modeling in design and translation of microfluidic Organ-on-Chips
Narasimhan Sriram, Hesperos Inc., USA
6. How Organ-on-Chip Technology is Revolutionizing Drug Discovery
Sepand Bafti, Nortis, USA
7. How to effectively use human microphysiological systems to assess ADME properties of novel drug compounds
Tomasz Kostrzewski, Emily Richardson, CN-Bio, United Kingdom
8. Clinically Relevant Testing of Diseased Neuromuscular Junctions for Evaluation and Therapeutic Recovery of Functional Deficits
Virginia Smith, Hesperos Inc., USA
9. Predicting Drug-Induced Liver Injury Caused by Small Molecules Using Human Liver-Chip
Goodwell Nzou, Emulate, USA
10. Hands-on the new innovative organs-on-chip tool kit: NeuroBento™
Thibault Honegger, NETRI, France
11. Connecting 2D and 3D models in a Multi-Organ-Chip for safety and efficacy evaluation
Thi Phuong Tao, Katharina Schimek, TissUse GmbH, Germany
- Adrian Roth, Roche, Switzerland
- Jan Lichtenberg, InSphero, Switzerland
- Nina Hobi, AlveoliX, Switzerland
- Anthony Bahinski, Vivodyne, Inc., USA
- Daniel Levner, Emulate, USA
- Suzanne Fitzpatrick, Food and Drug Administration, USA
- Noo Li Jeon, Seoul National University, South Korea
- Kaoru Sato, National Institute of Health Sciences, Japan
12:50 pm – 1:10 pm
137. Predictive Nephrotoxicity Testing of Ochratoxin A and Linkage to CKDu
Edward Kelly, University of Washington, USA
1:10 pm – 1:30 pm
79. Standalone Microphysiological System with Precise Oxygen Control for Intestinal-Microbial Interactions
Abhinav Bhushan, Illinois Institute of Technology, USA
1:30 pm – 1:50 pm
34. Characterizing the reproducibility of a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation – joint study by an MPS developer and a regulator
*Tomasz Kostrzewski, CN-Bio, UK
1:50 pm – 2:10 pm
136. Peristalsis-like deformations increase tumor cell intravasation through GABAergic signaling in a colorectal cancer-on-chip model
*Carly Strelez, University of Southern California, USA
12:50 pm – 1:10 pm
194. Peripheral Nervous System Platform towards Disease Modeling and Neurotoxicity
Ben Cappiello, Axosim, USA
1:10 pm – 1:30 pm
232. Human on a chip systems applied to neurodegenative rare diseases
James Hickman, University of Central Florida, Hesperos Inc., USA
1:30 pm – 1:50 pm
62. Multifluorescent human brain organoid model for high throughput chemical toxicity and drug efficacy screening.
Carolina Romero, Johns Hopkins University, USA
1:50 pm – 2:10 pm
199. Human stem cell-based retina on chip – a screening platform for retinal drug development
*Madalena Cipriano, Eberhard Karls University of Tübingen, Germany
12:50 pm – 1:10 pm
102. A microfluidic thyroid-liver platform to enable cross-species comparison of mechanisms of thyroid toxicity in rats and humans
Marian Raschke, Bayer AG, Germany
1:10 pm – 1:30 pm
130. Patient-specific human immunocompetent adipose tissue-on-chip models for obesity- and endocrinology research
*Julia Rogal, Eberhard Karls University of Tübingen, Germany
1:30 pm – 1:50 pm
82. A New Multi-Organ Microfluidic Device to Recapitulate Endocrine Signalling in Vitro: The LATTICE Platform.
*Hannes Campo, Northwestern University, USA
1:50 pm – 2:10 pm
189. A microphysiological system coupling of metabolic associated fatty liver disease (MAFLD) to endocrine pancreatic islets: Towards the association and causal link between MAFLD and Type 2 diabetes (T2D)
*Julio Aleman, University of Pittsburgh, USA
2:15 pm – 2:35 pm
88. Complex in vitro models Representing the Pulmonary System
Arno Gutleb, Luxembourg Institute of Science and Technology, Luxembourg
2:35 pm – 2:55 pm
44. Development of the Human-Relevant Aerosol Test Platform HUMIMIC–InHALES for Evaluating Respiratory Toxicity and Systemic Effects of Inhaled Aerosols
Kasper Renggli, Philip Morris International, USA
2:55 pm – 3:15 pm
100. An Advanced Drug Screening Platform for Respiratory Viruses
Mirjam Kiener, AlveoliX, Switzerland
3:15 pm – 3:35 pm
Title TBA
Marc Ferrer, National Institutes of Health, National Center for Advancing Translational Sciences, USA
2:15 pm – 2:35 pm
12. Microphysiological Systems for Immune Cell Trafficking and Capture
Steve George, UC Davis, Aracari Biosciences, USA
2:35 pm – 2:55 pm
180. Modeling Inflammatory Immune Cell Recruitment and Response on Human Colon Intestine-Chip
Chris Carman, Emulate, USA
2:55 pm – 3:15 pm
205. Engineered immunocompetent intestinal models: applications in cancer immunotherapy and beyond
Nikolche Gjorevski, Roche, Switzerland
3:15 pm – 3:35 pm
112. A microfluidic bone marrow chip for the safety profiling of complex large molecules in preclinical drug development
*Leopold Koenig, TissUse GmbH, Germany
2:15 pm – 2:35 pm
43. Multi-organ experiments scaled up
Olivier Frey, InSphero, Switzerland
2:35 pm – 2:55 pm
192. Multi-organ Microphysiological Systems as Tools to Understand Interorgan Crosstalk in Health and Disease
Martin Trapecar, Johns Hopkins University, USA
2:55 pm – 3:15 pm
144. InterOrgan multi-tissue chip system for linking matured tissue niches by vascular flow
*Kacey Ronaldson-Bouchard, Columbia University, USA
3:15 pm – 3:35 pm
11. Establishment of a human multi-organ-chip platform to replace animal transplant models for preclinical evaluation of Treg cell therapies
*Isabell Durieux, TissUse GmbH, Charité, Germany
3:40 pm – 4 pm
272. Neurovascular Organ Chips
Anna Herland, Karolinska, Sweden
4 pm – 4:20 pm
268. Human blood-brain barrier model empowered by an engineered basement membrane
Tae-Eun Park, Ulsan National Institute of Science and Technology, Korea
4:20 pm – 4:40 pm
250. Development of an in vitro 3D neuro-vascular model for Alzheimer’s disease
*Georgios Pavlou, Massachusetts Institute of Technology, USA
4:40 pm – 5 pm
227. Fluidic absorption drives cystogenesis in a human organoid-on-a-chip model of polycystic kidney disease
Benjamin Freedman, University of Washington, USA
3:40 pm – 4 pm
276. Validation of an MPS human tumor model: Vascularized colon cancer micro-tumors recapitulate in vivo drug responses
Chris Hughes, UC Irvine, Aracari Biosciences, USA
4 pm – 4:20 pm
15. Cardiovascular MPS models for disease and drug discovery
Christine Mummery, Leiden University, Netherlands
4:20 pm – 4:40 pm
110. Microgravity-Induced Mitochondrial Dysfunction in Human iPSC-Based 3D Cardiac Microphysiological System
*Devin Mair, Johns Hopkins University, USA
4:40 pm – 5 pm
215. Robust strategies for generating perfusable microvasculature-on-a-chip models for cancer studies.
*Zhengpeng Wan, Massachusetts Institute of Technology, USA
3:40 pm – 4 pm
269. ESTP/STP Collaboration on Complex In Vitro Models & Pathology
Dan Rudmann, Charles River, USA
4 pm – 4:20 pm
89. How to best guide the characterization of a thyroid-liver chip: The relevance of combining pathological and metabolic readouts
Julia Kühnlenz, Bayer SAS, CropScience, Pathology & Mechanistic Toxicology, Sophia Antipolis, France
4:20 pm – 4:40 pm
104. Complex In Vitro Models in Preclinical Toxicologic Pathology – Histotechniques and Examples
*Luisa Bell, University of Basal, Roche, Switzerland
4:40 pm – 5 pm
20. Neural Rosette ArraysTM for Quantitative High-Throughput Screening of Human Developmental Neurotoxicity and Teratogenicity
Randolph Ashton, University of Wisconsin-Madison, USA
Keynote: Donald E. Ingber, MD, PhD
Wyss Institute Harvard University, USA
Title: Recapitulating human biology, disease states, and therapeutic responses in vitro
Bio: Donald E. Ingber, MD, PhD is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University. Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads scientific and engineering teams that cross a broad range of disciplines to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology, and translational medicine, with his most recent pioneering contributions being the development of human Organ-on-Chips as replacements for animal testing and multiplexed electrochemical sensors for medical diagnostics. Through his work, Ingber has helped to break down boundaries between science, art and design, and has made great strides in translating his innovations into commercial products with many now either in clinical trials or currently being sold. He has authored more than 500 publications and over 170 U.S. patents, founded 7 companies, and has been a guest speaker at more than 550 events internationally. Ingber is a member of the National Academy of Medicine, National Academy of Engineering, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He also was listed among the Top 20 Translational Researchers in 2012, 2019, and 2020 (Nature Biotechnology).
Welcome Reception at Mark Twain Courtyard – Join us for a taste of New Orleans!
Keynote: Michael Shuler, PhD
Hesperos Inc., Cornell University, USA
Title: Body-on-a Chip: The Potential to Transform Drug Development
Bio: Michael L. Shuler is the Eckert Professor of Engineering, Emeritus in the Meing Department of Biomedical Engineering and in the Smith School of Chemical and Biomolecular Engineering at Cornell University. Shuler has degrees in chemical engineering (BS, Notre Dame, 1969 and Ph.D., Minnesota, 1973) and has been a faculty member at Cornell University since 1974. Shuler’s research includes development of “Body-on-a-Chip” for testing pharmaceuticals for toxicity and efficacy, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and construction of whole cell models relating genome to physiology. Shuler is President of Hesperos, a company founded to implement the “Body-on-a-Chip” system. He has an honorary doctorate from the University of Notre Dame. Shuler has been elected to the National Academy of Engineering and the American Academy of Arts and Science.
10:05 am – 10:30 am
210. Chemotherapy-Induced Peripheral Neuropathy Using a Nerve-on-a-Chip Microphysiological System
Lowry Curley, Axosim, USA
10:30 am – 10:55 am
17. Engineering spatially organized organs-on-chips
Liliana Moreira Teixera, University of Twente, Netherlands
10:55 am – 11:15 am
259. Biophysical and Biochemical Determinants of Angiogenesis into Synthetic PEG Hydrogels from Perfusable Microvasculature
*Ellen Kan, Massachusetts Institute of Technology, USA
11:15 am – 11:35 am
150. Classical Complement Pathway Inhibition in a ‘Human-on-a-Chip’ Model of Autoimmune Demyelinating Neuropathies
Christopher McAleer, Hesperos Inc., USA
11:35 am – 11:55 am
182. Electrical pulse stimulation and compounds with anti-atrophic potential influence contractile response of patient-derived skeletal muscle cells in a microphysiological system
*Jorge A. Mojica-Santiago, University of Florida, USA
10:05 am – 10:30 am
267. A novel immunocompetent MPS platform for modeling the cross-talk between 3D tumor tissues and circulating immune cells
Silvia Scaglione, React4Life, Italy
10:30 am – 10:55 am
226. Organ-on-Chip models recapitulating complex human immunocompetent tissues
Peter Loskill, Eberhard Karls University of Tübingen, Germany
10:55 am – 11:20 am
279. Tonsil organoids to investigate human adaptive immunity
Lisa Wagar, University of California, USA
11:20 am – 11:40 am
107. Development of a lymphoid organ-on-chip to evaluate CD4+ T cell/B cell interactions
*Raphaël Jeger-Madiot, Université de Paris, France
11:40 am – 12 pm
54. Induced Pluripotent Stem Cell-Derived Neural Organoids Incorporating Microglia for Interrogation of Neural Inflammation
Connie Lebakken, Stem Pharm Incorporated, USA
1. Ivan Rusyn, Texas A&M University, USA
2. Lorna Ewart, Emulate, USA
3. Annie Moisan, HOPE, Switzerland
4. Jason Ekert, GlaxoSmithKline, UK
1:25 pm – 1:45 pm
281. Standards supporting innovation: the case of Organ-on-Chip
Monica Piergiovanni, European Commission Joint Research Centre (JRC), Italy
1:45 pm – 2:05 pm
22. Open Platform Technology for Organs-on-Chips
Andries Van der Meer, University of Twente, Netherlands
2:05 pm – 2:25 pm
287. Standards for integrating heterogenous data and metadata from organ-on-chip technologies
Martin Golebiewski, Heidelberg Institute for Theoretical Studies, Germany
2:25 pm – 2:45 pm
278. Guidelines for microfluidics: how to simplify your OoC Life ?
Nicolas Verplanck, Université Grenoble Alpes, CEA, LETI, France
3 pm – 3:25 pm
213. Systems engineering of microphysiometry
Joachim Wiest, cellasys, Germany
3:25 pm – 3:50 pm
74. Identification of variation factors for the development of assays using MPS
Yuzuru Ito, Tsukuba University, Japan
3:50 pm – 4:10 pm
75. Circadian physiology in microphysiological systems
Alastair Stewart, University of Melbourne, Australia
4:10 pm – 4:30 pm
174. Development of a Functional Human iPSC-Cortical Neuron-MEA Model for Long Term Potentiation Analysis and Alzheimer’s Drug Testing
*Kaveena Autar, University of Central Florida, USA
4:30 pm – 4:50 pm
253. IQ MPS Affiliates: Accelerating the development and adoption of MPS models in industry
Kimberly Homan, IQ MPS Affiliate, USA
3 pm – 3:25 pm
97. A PBPK-compliant human intestine-liver-brain-kidney Chip for QIVIVE in drug development
Reyk Horland, TissUse GmbH, Germany
3:25 pm – 3:50 pm
118. A continuous, automated perfusion culture and analysis system (CAPCAS) to enable massive parallelization of organs-on-chips, chemostats, and other miniature bioreactors
John Wikswo, Vanderbilt University, USA
3:50 pm – 4:10 pm
134. Modeling doxorubicin’s pharmacokinetics and pharmacodynamics in a human InterOrgan chip
*Diogo Teles, Columbia University, USA
4:10 pm – 4:30 pm
258. Biodistribution and PK modeling of a multi-organ human-on-a-chip system consisting of a GI tract, blood brain barrier and neurons
*Narasimhan Sriram, Hesperos Inc., USA
4:30 pm – 4:50 pm
129. Using in vitro cell models, kidney MPS, and PBPK modeling to predict human renal clearance: health, disease, and drug interaction
Catherine K. Yeung, University of Washington, USA
Poster presentations for abstracts 1-156, 291-300
Drinks and snacks available
Macro Party – separate registration
The Civic, 510 O’Keefe Ave, New Orleans, LA 70113 – SEPARATE TICKET REQUIRED
8:00 PM-11:00 PM CDT
Music by Louisiana Spice Band
8:50 am – 9:15 am
46. A microphysiological system representing liver fibrosis, the concept of AOP-Chip
Laura Suter-Dick, School of Life Sciences FHNW, Switzerland
9:15 am – 9:40 am
76. Astronaut-on-a-chip: human, multi-organ platform for assessing extended effects of cosmic radiation
*Daniel Naveed Tavakol, Columbia University, USA
9:40 am – 10 am
235. Integrated human intestine–liver-on-a-chip to elucidate liver injury induced by free fatty acid receptor 1 agonists
*Ilona Wehl, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
10 am – 10:20 am
119. 3D Nephroscreen: high throughput drug-induced nephrotoxicity screening on a microfluidic proximal tubule model
*Kristin Bircsak, MIMETAS, Netherlands
10:20 am – 10:40 am
90. Dynamic lung inhalation-on-chip: A triple co-culture cellular platform to predict toxicity of aerosolized irritants
*Arunima Sengupta, ARTORG, Organs-on-Chip Technologies, Switzerland
8:50 am – 9:15 am
221. The BioSystics Analytics Platform: A comprehensive analytical platform creating actionable knowledge from MPS and other in vitro models to advance human health and safety.
Joe Maggiore, University of Pittsburgh, USA
9:15 am – 9:40 am
289. Development of image-based analysis to support High Throughput Screening using complex biology on MPS
Sanghee Yoo, Qureator, USA
9:40 am – 10:05 am
275. Organs-on-chips – are we ready for fit-for-use?
*Nuria Roldan, AlveoliX, Switzerland
10:05 am – 10:25 am
188. PREDICT96: Demonstrating high-throughput diverse complex tissue, therapeutic efficacy screening, and biomarker identification
Timothy Petrie, The Charles Stark Draper Laboratory, USA
10:25 am – 10:45 am
160. A 3D-optimized microplate enables spheroid production, long-term cultivation, and confocal high content imaging with cell-level resolution in a single plate
Judith Wardwell-Swanson, InSphero, Switzerland
1. Suzanne Fitzpatrick, Food and Drug Administration, USA
2. Jean-Lou Dorne, European Food Safety Authority, Italy
3. Anne Gourmelon, Organization for Economic Co-operation and Development (OECD) Test Guidelines Programme, France
4. Maurice Whelan, European Commission Joint Research Centre (JRC), Italy
5. Seiichi Ishida, National Institute of Health Sciences, Japan
2:25 pm – 2:50 pm
288. Biophysics-based computational modeling as a tool for translational research and drug screening in microphysiological systems
Jari Hyttinen, Centre of Excellence in Body-on-Chip Research, Tampere University, Finland
2:50 pm – 3:15 pm
277. Organoid Intelligence (O.I.): the new frontier in biocomputing and intelligence-in-a-dish
Lena Smirnova, Johns Hopkins University, USA
3:15 pm – 3:35 pm
177. A Multiscale Computational Framework for Modeling Microphysiological Systems
Carrie German, CFD Research Corporation, USA
3:35 pm – 3:55 pm
4. Machine learned vascularized networks improve predictive power of organ-chips
*James Tronolone, Texas A&M University, USA
3:55 pm – 4:15 pm
56. Ex vivo human 3D NASH model as a screening-based discovery approach for selecting and prioritizing drug candidates
Sue Grepper, InSphero, Switzerland
2:25 pm – 2:50 pm
273. Biofabrication of kidney proximal tubules and other organ structures in organ-on-chip devices
Thomas Neumann, Nortis. USA
2:50 pm – 3:15 pm
286. Instrumented Microphysiological Analytic Platforms for Precision Measurement and Manipulation of Tissue Functions
Devin Mair, Johns Hopkins University, USA
3:15 pm – 3:35 pm
261. Engineering next generation organoids with automated lab workflows.
Magdalena Kasendra, Cincinnati Children’s Hospital Medical Center, USA
3:35 pm – 3:55 pm
260. Rapid 3D-Bioprinting of a Microfluidic Tissue Model of Glioblastoma
*Riccardo Barrile, University of Cincinnati, USA
3:55 pm – 4:15 pm
32. A Novel Tissue Bioreactor For Retinal Organoid Microenvironmental Control
*Emma Drabbe, University of Miami, USA
4:30 pm – 4:50 pm
52. Modeling preterm birth in vitro using a Feto-Maternal interface Organ-On-Chip
*Lauren Richardson, University of Texas Medical Branch, USA
4:50 pm – 5:10 pm
64. Human host-microbiome interactions and mucus physiology modeled in Cervix and Vagina Chips
Zohreh Izadifar, Wyss Institute Harvard University, USA
5:10 pm – 5:30 pm
127. The development of a high-throughput screening platform to identify ovarian endocrine disrupting chemicals using a 3D alginate encapsulated in vitro follicle growth system
Shuo Xiao, Rutgers University, USA
5:30 pm – 5:50 pm
245. Modeling Endometrial-Immune Crosstalk in Micro-Physiological Systems
*Jeremy Huang, Massachusetts Institute of Technology, USA
Poster presentations for abstracts 157-282, 303-320
Drinks and snacks provided
Keynote: Linda Griffith, PhD
Massachusetts Institute of Technology, USA
Title: Deconstructing and Reconstructing the Patient
9 am – 9:25 am
146. Organismoids – aiming for ultimate precision in patient-specific treatment selection
Uwe Marx, TissUse GmbH, Germany
9:25 am – 9:50 am
211. Human Tissue Models supporting Clinical Development & Personalized Medicine
Adrian Roth, Roche, Switzerland
9:50 am – 10:10 am
159. A patient-derived lung-on-chip model for immunotherapy safety assessment
*Giulia Raggi, AlveoliX, Switzerland
10:10 am – 10:30 am
307. A patient-derived iPSC liver acinus microphysiology system is an innovative precision medicine platform for optimizing clinical trial design of nonalcoholic fatty liver disease
*Mengying Xia, University of Pittsburgh Drug Discovery Institute, USA
10:30 am – 10:50 am
252. Microvascular Model Incorporating Cancer-Associated Fibroblasts and Immune Cell Perfusion
Sarah Shelton, Massachusetts Institute of Technology, USA
9 am – 9:25 am
274. Organ-on-a-Chip models in early stage drug discovery: A phenotypic screening exercise
Paul Vulto, MIMETAS, Netherlands
9:25 am – 9:50 am
77. Implementation of microphysiological system in a pharmaceutical company
Kazuhiro Tetsuka, Astellas Pharma, Japan
9:50 am – 10:15 am
122. Towards a comprehensive osteoarthritis modelling on-chip: controlled mechanical stimulation in bi-layered micro-tissues compartments
Marco Rasponi, Politecnico di Milano, Italy
10:15 am – 10:35 am
172. Assessing Contractility of 3D iPSC-Derived Muscle Models for Safety and Discovery Using a Novel, High-Throughput, and Label-Free Instrumentation Platform
Nicholas Geisse, Curi Bio Inc., USA
10:35 am – 10:55 am
179. Modeling skeletal muscle fibrosis and vascular interactions using a human microphysiological system
Qiao Zhang, Duke University, USA
11:05 am – 11:30 am
270. MPSCoRe: a global working group applying open science to tackling a pandemic
Nicole Kleinstreuer, National Institute of Environmental Health Sciences, NTP Interagency Center for the Evaluation of Alternative Toxicological Methods, USA
11:30 am – 11:55 am
237. A Complete Platform for Preclinical Trials of Non-Alcoholic Fatty Liver Disease Including a Patient-Specific, Human, Biomimetic Liver Microphysiology System and a Portal to the BioSystics, Inc Analytical Platform
Lans Taylor, University of Pittsburgh, USA
11:55 am – 12:20 pm
285. From Good Cell and Tissue Culture Practice (GCCP 2.0) to Good In Vitro Reporting Standards (GIVReSt)
Thomas Hartung, Johns Hopkins University, USA
12:20 pm – 12:40 pm
139. Industry perspective on the challenges and opportunities in developing, selecting and applying advanced in vitro models to drug development in the context of data-driven decision making.
Daniela Ortiz Franyuti, Roche, Switzerland
12:40 pm – 1 pm
41. Neural network analytics as a biomarker for preclinical brain-on-chip assays
Thibault Honegger, NETRI, France
11:05 am – 11:30 am
290. Embracing diversity in a microphysiological world
Trivia Frazier, Obatala Science, USA
11:30 am – 11:55 am
200. Hemorheology and pathophysiology of COVID-19 induced thrombosis predicted by Vein-Chip
Abhishek Jain, Texas A&M University, USA
11:55 am – 12:15 pm
48. uScar: a mechanically active model of human cardiac fibrosis on chip
*Paola Occhetta, Politecnico di Milano, Italy
12:15 pm – 12:35 pm
69. Human Tendon-on-Chip (hToC) platform for modeling inflammation, fibrosis, and cell cycle regulation in fibrovascular tendon healing
*Raquel Ajalik, University of Rochester, USA
12:35 pm – 12:55 pm
96. Modeling ischemic stroke in a triculture neurovascular unit on-a-chip
*Desiree Goubert, MIMETAS, Netherlands
Yasuyuki Sakai, University of Tokyo
Megan LaFollette, The North American 3Rs Collaborative, USA
Young-Jae Cho, Seoul National University Bundang Hospital, South Korea
Alastair Stewart, University of Melbourne, Australia
Zhongze Gu, Southeast University in Nanjing, China and Kaiming Ye, Southeast University in Nanjing, China
Peter Loskill, EUROoCS, Europe
Ben Maoz, Sagol School of Neuroscience, Tel Aviv University, Israel
Octavio Presgrave, BRACVAM, Brazil